Literature DB >> 16034719

Tumor necrosis factor alpha system and plasma adiponectin concentration in women with gestational diabetes.

M Kinalski1, B Telejko, M Kuźmicki, A Kretowski, I Kinalska.   

Abstract

Plasma concentrations of adiponectin, tumor necrosis factor-alpha (TNF-alpha) and its soluble receptors sTNFR-1 and sTNFR-2 were measured in 80 patients with gestational diabetes (GDM) (mean age 29.0 +/- 4.9 years) and 30 pregnant women with normal glucose tolerance (NGT) (mean age 28.2 +/- 6.0 years). We found that GDM patients had significantly lower concentrations of adiponectin (11.28 +/- 5.91 vs. 16.31 +/- 6.04 microg/ml, p = 0.00009) and elevated levels of TNF-alpha (1.71 +/- 0.92 vs. 1.27 +/- 0.42 pg/ml, p = 0.0175) in comparison to NGT women. The differences remained statistically significant after adjusting for BMI. Plasma levels of sTNFR-1 and sTNFR-2 also tended to be higher in GDM patients. In the GDM group TNF-alpha concentrations correlated significantly with sTNFR-1 (r = 0.444, p = 0.00008), sTNFR-2 (r = 0.364, p = 0.0016) and with C-peptide concentrations (r = 0.318, p = 0.016), whereas in women with NGT TNF-alpha correlated only with TG levels (r = 0.50, p = 0.024). Multivariate linear regression analysis revealed that prepregnant BMI was the most predictive indicator of TNF-alpha concentrations in GDM women. TG concentrations as well as BMI before pregnancy and at the time of sampling in pregnant NGT women were significant predictors, explaining 62% of the variance in TNF-alpha concentration. There were also negative correlations between adiponectin concentrations and a pregestational BMI (r = - 0.298, p = 0.009), BMI at the time of sampling (r = - 0.239, p = 0.034) and TG concentrations (r = - 0.379, p = 0.039) in GDM patients, whereas women with NGT showed only a negative correlation between adiponectin and TG concentrations (r = - 0.488, p = 0.025). In a multivariate regression analysis, prepregnancy BMI and TG levels remained significant predictors, explaining 39% of the variation in plasma adiponectin concentration in GDM women. In conclusion, our results suggest that decreased adiponectin concentration in GDM may not simply reflect maternal adiposity and insulin resistant state, but may contribute to the impaired glucose metabolism during pregnancy, with potential implications for screening and prevention of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034719     DOI: 10.1055/s-2005-870238

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  38 in total

Review 1.  Maternal Microbiome and Pregnancy Outcomes That Impact Infant Health: A Review.

Authors:  Anne L Dunlop; Jennifer G Mulle; Erin P Ferranti; Sara Edwards; Alexis B Dunn; Elizabeth J Corwin
Journal:  Adv Neonatal Care       Date:  2015-12       Impact factor: 1.968

2.  Associations between adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations and biomarkers of inflammation, hormonal, and insulin response.

Authors:  Fred K Tabung; Teresa T Fung; Jorge E Chavarro; Stephanie A Smith-Warner; Walter C Willett; Edward L Giovannucci
Journal:  Int J Cancer       Date:  2016-11-14       Impact factor: 7.396

Review 3.  Some of the experimental and clinical aspects of the effects of the maternal diabetes on developing hippocampus.

Authors:  Javad Hami; Fatemeh Shojae; Saeed Vafaee-Nezhad; Nasim Lotfi; Hamed Kheradmand; Hossein Haghir
Journal:  World J Diabetes       Date:  2015-04-15

4.  Maternal visfatin concentration in normal pregnancy.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Edi Vaisbuch; Offer Erez; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Chia-Ling Nhan-Chang; Percy Pacora; Francesca Gotsch; Lami Yeo; Sun Kwon Kim; Samuel S Edwin; Sonia S Hassan; Pooja Mittal
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

Review 5.  Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms.

Authors:  Ryan J Van Lieshout; Lakshmi P Voruganti
Journal:  J Psychiatry Neurosci       Date:  2008-09       Impact factor: 6.186

6.  Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Edi Vaisbuch; Offer Erez; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Chia-Ling Nhan-Chang; Percy Pacora; Francesca Gotsch; Lami Yeo; Sun Kwon Kim; Samuel S Edwin; Sonia S Hassan; Pooja Mittal
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

7.  Maternal serum adiponectin multimers in gestational diabetes.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Edi Vaisbuch; Offer Erez; Pooja Mittal; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Percy Pacora; Lami Yeo; Francesca Gotsch; Zhong Dong; Bo Hyun Yoon; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

8.  Maternal serum adiponectin multimers in patients with a small-for-gestational-age newborn.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Edi Vaisbuch; Offer Erez; Pooja Mittal; Tinnakorn Chaiworapongsa; Sun Kwon Kim; Percy Pacora; Lami Yeo; Francesca Gotsch; Zhong Dong; Bo Hyun Yoon; Sonia S Hassan; Juan Pedro Kusanovic
Journal:  J Perinat Med       Date:  2009       Impact factor: 1.901

Review 9.  Gestational diabetes, inflammation, and late vascular disease.

Authors:  L Volpe; G Di Cianni; C Lencioni; I Cuccuru; L Benzi; S Del Prato
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

10.  Characterization of visceral and subcutaneous adipose tissue transcriptome in pregnant women with and without spontaneous labor at term: implication of alternative splicing in the metabolic adaptations of adipose tissue to parturition.

Authors:  Shali Mazaki-Tovi; Adi L Tarca; Edi Vaisbuch; Juan Pedro Kusanovic; Nandor Gabor Than; Tinnakorn Chaiworapongsa; Zhong Dong; Sonia S Hassan; Roberto Romero
Journal:  J Perinat Med       Date:  2016-10-01       Impact factor: 1.901

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.